Form 4: Beth Hecht Sells Xeris Biopharma Shares

Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc., reported a sale of common stock executed under a Rule 10b5-1 trading plan.

Summary

• Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc. (XERS), sold 16,667 shares of common stock.
• The transaction occurred on April 1, 2026, and was executed under a Rule 10b5-1 trading plan.
• The sale was conducted at a weighted average price of $5.9914 per share, with individual transactions ranging from $5.890 to $6.085.
• Following the transaction, Beth Hecht beneficially owns 1,209,840 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While it involves an insider selling stock, the sale was executed under a pre-established Rule 10b5-1 trading plan, mitigating immediate negative sentiment.

Negatives

• Insider selling of company stock can sometimes be perceived negatively by the market, although this sale was conducted under a pre-arranged trading plan.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a stock transaction by an insider.

Industry Context

StockSavvy.ai notes that insider sales, even those conducted under Rule 10b5-1 plans, are closely watched by investors as they can signal management's view on the company's valuation. However, the existence of a 10b5-1 plan suggests the sale was pre-planned and not necessarily a reaction to new, non-public information.

Stakeholder Impact

• Shareholders may observe this transaction, but the Rule 10b5-1 plan indicates it was pre-scheduled and not necessarily a reflection of current negative sentiment.

Key Dates

Keywords

Xeris Biopharma Holdings, XERS, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Beth Hecht, Common Stock, Beneficial Ownership